JPWO2022071601A1 - - Google Patents

Info

Publication number
JPWO2022071601A1
JPWO2022071601A1 JP2022554159A JP2022554159A JPWO2022071601A1 JP WO2022071601 A1 JPWO2022071601 A1 JP WO2022071601A1 JP 2022554159 A JP2022554159 A JP 2022554159A JP 2022554159 A JP2022554159 A JP 2022554159A JP WO2022071601 A1 JPWO2022071601 A1 JP WO2022071601A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022554159A
Other languages
Japanese (ja)
Other versions
JPWO2022071601A5 (https=
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2022071601A1 publication Critical patent/JPWO2022071601A1/ja
Publication of JPWO2022071601A5 publication Critical patent/JPWO2022071601A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/165Coronaviridae, e.g. avian infectious bronchitis virus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/60Complex ways of combining multiple protein biomarkers for diagnosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2022554159A 2020-10-02 2021-10-01 Pending JPWO2022071601A1 (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020168107 2020-10-02
PCT/JP2021/036525 WO2022071601A1 (ja) 2020-10-02 2021-10-01 血中エクソソームのタンパク質マーカーを利用したcovid-19重症化予測方法

Publications (2)

Publication Number Publication Date
JPWO2022071601A1 true JPWO2022071601A1 (https=) 2022-04-07
JPWO2022071601A5 JPWO2022071601A5 (https=) 2024-10-09

Family

ID=80951770

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022554159A Pending JPWO2022071601A1 (https=) 2020-10-02 2021-10-01

Country Status (5)

Country Link
US (1) US20240263234A1 (https=)
EP (1) EP4223887A4 (https=)
JP (1) JPWO2022071601A1 (https=)
CN (1) CN114556105A (https=)
WO (1) WO2022071601A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023007809A1 (ja) * 2021-07-29 2023-02-02 国立大学法人東北大学 コロナウイルス感染症の重症化リスクの評価方法、およびコロナウイルス感染症の重症化リスク評価キット
CN115097147B (zh) * 2022-08-23 2022-11-25 细胞生态海河实验室 预测奥密克戎复阳风险的生物标志物及代谢、蛋白、联合模型
KR20250107848A (ko) 2022-11-07 2025-07-14 아이에스엠 가부시키가이샤 코트머단백질 복합체 서브유닛 베타2에 대한 항체
WO2024181522A1 (ja) * 2023-02-28 2024-09-06 国立大学法人大阪大学 Covid-19を検査する方法
CN117467598B (zh) * 2023-12-28 2024-05-10 健颐生物科技发展(山东)有限公司 肝细胞源pcsk9外泌体的制备方法
WO2025170060A1 (ja) * 2024-02-08 2025-08-14 学校法人慈恵大学 急性肺障害治療薬
CN119177277B (zh) * 2024-10-08 2025-05-27 北京医院 与结肠癌细胞对吉西他滨耐药性相关的circ86591的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2697653B1 (en) * 2011-04-15 2016-03-30 Children's Medical Center Corporation Diagnostic markers and therapeutic targets of kawasaki disease
CN111366728A (zh) * 2020-03-27 2020-07-03 重庆探生科技有限公司 一种用于检测新型冠状病毒SARS-CoV-2的免疫层析试剂盒

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AN, P. ET AL.: "Biochemical indicators of coronavirus disease 2019 exacerbation and the clinical implications", PHARMACOLOGICAL RESEARCH, JPN6020034567, 23 May 2020 (2020-05-23), ISSN: 0005785563 *
FUJITA, YU ET AL.: "Early prediction of COVID-19 severity using extracellular vesicle COPB2", JOURNAL OF EXTRACELLULAR VESICLES, vol. 10, JPN6021049874, 2 June 2021 (2021-06-02), pages 12092, ISSN: 0005785565 *
LI, HUAN ET AL.: "Serum Amyloid A is a biomarker of severe Coronavirus Disease and poor prognosis", JOURNAL OF INFECTION, vol. 80, JPN6021049875, June 2020 (2020-06-01), pages 646 - 655, ISSN: 0005785564 *
SKEVAKI, C., ET AL: "Laboratory characteristics of patients infected with the novel SARS-CoV-2 virus", JOURNAL OF INFECTION, JPN6021034619, 21 June 2020 (2020-06-21), ISSN: 0005785561 *
WANG, C-Z. ET AL.: "Early risk factors of the exacerbation of coronavirus disease 2019 pneumonia", JOURNAL OF MEDICAL VIROLOGY, JPN6020034568, 29 May 2020 (2020-05-29), ISSN: 0005785562 *
植田幸嗣ほか: "エクソソームのプロテオーム解析によるバイオマーカー開発", 医学のあゆみ, vol. 251, no. 10, JPN6021049873, 6 December 2014 (2014-12-06), pages 975 - 979, ISSN: 0005785566 *

Also Published As

Publication number Publication date
EP4223887A8 (en) 2023-11-22
EP4223887A1 (en) 2023-08-09
WO2022071601A1 (ja) 2022-04-07
EP4223887A4 (en) 2024-10-30
CN114556105A (zh) 2022-05-27
US20240263234A1 (en) 2024-08-08
TW202223104A (zh) 2022-06-16

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
JPWO2022071601A1 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
JPWO2023007809A1 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241001

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260403